CUMMINS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CUMMINS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.67B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $34.10B | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $34.07B | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $28.07B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $24.02B | Feb 12, 2024 |
| FY2020 | Dec 31, 2020 | $5.83B | Feb 10, 2021 |
| FY2020 | Sep 27, 2020 | $5.12B | Feb 10, 2021 |
| FY2020 | Jun 28, 2020 | $3.85B | Feb 10, 2021 |
| FY2020 | Mar 29, 2020 | $5.01B | Feb 10, 2021 |
| FY2020 | Dec 31, 2019 | $5.58B | Feb 10, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $5.48B | Feb 14, 2018 |
| FY2017 | Oct 1, 2017 | $5.29B | Feb 14, 2018 |
| FY2017 | Jul 2, 2017 | $5.08B | Feb 14, 2018 |
| FY2017 | Apr 2, 2017 | $4.59B | Feb 14, 2018 |
| FY2017 | Dec 31, 2016 | $4.50B | Feb 14, 2018 |
| FY2017 | Oct 2, 2016 | $4.19B | Feb 14, 2018 |
| FY2017 | Jul 3, 2016 | $4.53B | Feb 14, 2018 |
| FY2017 | Apr 3, 2016 | $4.29B | Feb 14, 2018 |
| FY2016 | Dec 31, 2015 | $4.77B | Feb 13, 2017 |
| FY2016 | Sep 27, 2015 | $4.62B | Feb 13, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.52B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $8.44B | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $8.25B | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $6.72B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $5.70B | Feb 12, 2024 |
| FY2020 | Dec 31, 2020 | $1.36B | Feb 10, 2021 |
| FY2020 | Sep 27, 2020 | $1.35B | Feb 10, 2021 |
| FY2020 | Jun 28, 2020 | $890.00M | Feb 10, 2021 |
| FY2020 | Mar 29, 2020 | $1.29B | Feb 10, 2021 |
| FY2020 | Dec 31, 2019 | $1.31B | Feb 10, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Dec 31, 2010 | $1.04B | Feb 24, 2011 |
| FY2009 | Dec 31, 2009 | $428.00M | Feb 26, 2010 |
| FY2009 | Dec 31, 2008 | $755.00M | Feb 26, 2010 |
| FY2009 | Dec 31, 2007 | $739.00M | Feb 26, 2010 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.03B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $3.75B | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $1.76B | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $2.93B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $2.71B | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $2.27B | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $2.70B | Feb 8, 2022 |
| FY2020 | Dec 31, 2018 | $2.79B | Feb 10, 2021 |
| FY2019 | Dec 31, 2017 | $2.33B | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $1.88B | Feb 11, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.40B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $1.46B | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $1.50B | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $1.28B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $1.09B | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $906.00M | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $1.00B | Feb 8, 2022 |
| FY2020 | Dec 31, 2018 | $902.00M | Feb 10, 2021 |
| FY2019 | Dec 31, 2017 | $754.00M | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $637.00M | Feb 11, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.13B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $3.28B | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $3.33B | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $2.69B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $2.37B | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $2.13B | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $2.45B | Feb 8, 2022 |
| FY2020 | Dec 31, 2018 | $2.44B | Feb 10, 2021 |
| FY2019 | Dec 31, 2017 | $2.43B | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $2.10B | Feb 11, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.62B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $1.49B | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $3.97B | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $1.96B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $2.26B | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $2.72B | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $3.18B | Feb 8, 2022 |
| FY2020 | Dec 31, 2018 | $2.38B | Feb 10, 2021 |
| FY2019 | Dec 31, 2017 | $2.28B | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $1.94B | Feb 11, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.24B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $1.21B | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $1.21B | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $916.00M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $734.00M | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $528.00M | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $700.00M | Feb 8, 2022 |
| FY2020 | Dec 31, 2018 | $709.00M | Feb 10, 2021 |
| FY2019 | Dec 31, 2017 | $506.00M | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $531.00M | Feb 11, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.99B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $31.54B | Feb 10, 2026 |
| FY2024 | Dec 31, 2023 | $32.01B | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | $30.30B | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | $23.71B | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $22.62B | Feb 8, 2022 |
| FY2020 | Dec 31, 2019 | $19.74B | Feb 10, 2021 |
| FY2020 | Dec 31, 2018 | $19.06B | Feb 10, 2021 |
| FY2019 | Dec 31, 2017 | $18.08B | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $15.01B | Feb 11, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.58B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $20.23B | Feb 10, 2026 |
| FY2024 | Dec 31, 2023 | $22.10B | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | $20.07B | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | $14.31B | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $13.64B | Feb 8, 2022 |
| FY2020 | Dec 31, 2019 | $11.27B | Feb 10, 2021 |
| FY2019 | Dec 31, 2018 | $10.80B | Feb 11, 2020 |
| FY2018 | Dec 31, 2017 | $9.91B | Feb 11, 2019 |
| FY2017 | Dec 31, 2016 | $7.84B | Feb 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.35B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $10.27B | Feb 10, 2026 |
| FY2024 | Dec 31, 2023 | $8.85B | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | $8.98B | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | $8.15B | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $8.06B | Feb 8, 2022 |
| FY2020 | Dec 31, 2019 | $7.51B | Feb 10, 2021 |
| FY2019 | Dec 31, 2018 | $7.35B | Feb 11, 2020 |
| FY2018 | Dec 31, 2017 | $7.26B | Feb 11, 2019 |
| FY2017 | Dec 31, 2016 | $6.88B | Feb 14, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.22B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $2.37B | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $2.50B | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $2.34B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $1.29B | Feb 12, 2024 |
| FY2022 | Dec 31, 2020 | $1.29B | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $1.29B | Feb 8, 2022 |
| FY2020 | Dec 31, 2018 | $1.13B | Feb 10, 2021 |
| FY2019 | Dec 31, 2017 | $1.08B | Feb 11, 2020 |
| FY2018 | Dec 31, 2016 | $480.00M | Feb 11, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.62B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $20.83B | Feb 10, 2026 |
| FY2024 | Dec 31, 2023 | $17.85B | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | $18.04B | Feb 12, 2024 |
| FY2022 | Dec 31, 2021 | $16.74B | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $15.42B | Feb 8, 2022 |
| FY2020 | Dec 31, 2019 | $14.42B | Feb 10, 2021 |
| FY2019 | Dec 31, 2018 | $12.92B | Feb 11, 2020 |
| FY2018 | Dec 31, 2017 | $11.46B | Feb 11, 2019 |
| FY2017 | Dec 31, 2016 | $11.04B | Feb 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $2.10B | Feb 14, 2023 |
| FY2022 | Dec 31, 2021 | $2.59B | Feb 14, 2023 |
| FY2022 | Dec 31, 2020 | $3.40B | Feb 14, 2023 |
| FY2022 | Dec 31, 2019 | $1.13B | Feb 14, 2023 |
| FY2021 | Dec 31, 2018 | $1.30B | Feb 8, 2022 |
| FY2020 | Dec 31, 2017 | $1.37B | Feb 10, 2021 |
| FY2019 | Dec 31, 2016 | $1.12B | Feb 11, 2020 |
| FY2018 | Dec 31, 2015 | $1.71B | Feb 11, 2019 |
| FY2017 | Dec 31, 2014 | $2.30B | Feb 14, 2018 |
| FY2016 | Dec 31, 2013 | $2.70B | Feb 13, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $1.63B | Feb 18, 2014 |
| FY2013 | Dec 31, 2012 | $653.00M | Feb 18, 2014 |
| FY2011 | Dec 31, 2011 | $638.00M | Feb 21, 2012 |
| FY2010 | Dec 31, 2010 | $636.00M | Feb 24, 2011 |
| FY2010 | Dec 31, 2009 | $561.00M | Feb 24, 2011 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 20 | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | 28 | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | 15 | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | 14 | Feb 12, 2024 |
| FY2020 | Dec 31, 2020 | 3 | Feb 10, 2021 |
| FY2020 | Sep 27, 2020 | 3 | Feb 10, 2021 |
| FY2020 | Jun 28, 2020 | 1 | Feb 10, 2021 |
| FY2020 | Mar 29, 2020 | 3 | Feb 10, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 10, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 20 | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | 28 | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | 15 | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | 14 | Feb 12, 2024 |
| FY2020 | Dec 31, 2020 | 3 | Feb 10, 2021 |
| FY2020 | Sep 27, 2020 | 3 | Feb 10, 2021 |
| FY2020 | Jun 28, 2020 | 1 | Feb 10, 2021 |
| FY2020 | Mar 29, 2020 | 3 | Feb 10, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 10, 2021 |